Literature DB >> 15252279

Working memory deficits in adult rats after prenatal disruption of neurogenesis.

R Gourevitch1, C Rocher, G Le Pen, M-O Krebs, T M Jay.   

Abstract

We investigated the cognitive consequences of a prenatal injection of the mitotic inhibitor methylazoxymethanol (MAM) into pregnant rats at embryonic day 15 (E15) or 17 (E17). The male offspring were tested when adult on a version of the radial-arm maze task that assesses spatial working memory with an extended delay, where performance is dependent, in part, on the hippocampal-prefrontal circuit. A major impairment of spatial learning was observed in E15 MAM rats. However, the E17 MAM rats did learn the rule but were impaired selectively in the 30-min delay-interposed task. Morphologically, the E15 MAM rats exhibited dramatic gross brain abnormalities, whereas the E17 MAM animals displayed aberrant cell migration in the hippocampus and a disrupted laminar pattern in the neocortex. These results suggest that late gestational MAM injection (E17) causes a cognitive impairment in a prefrontal cortex-hippocampus-dependent working memory task. This approach could provide a new developmental model of disorders associated with working memory deficits, such as schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252279     DOI: 10.1097/01.fbp.0000135703.48799.71

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  42 in total

Review 1.  Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.

Authors:  Christina Wilson; Alvin V Terry
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-07

Review 2.  Disruption of cortical-limbic interaction as a substrate for comorbidity.

Authors:  A A Grace
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

Review 3.  Hippocampal sharp wave-ripple: A cognitive biomarker for episodic memory and planning.

Authors:  György Buzsáki
Journal:  Hippocampus       Date:  2015-10       Impact factor: 3.899

4.  A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia.

Authors:  Holly Moore; J David Jentsch; Mehdi Ghajarnia; Mark A Geyer; Anthony A Grace
Journal:  Biol Psychiatry       Date:  2006-04-11       Impact factor: 13.382

Review 5.  Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 6.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

7.  Disruption of prefrontal cortical-hippocampal balance in a developmental model of schizophrenia: reversal by sulpiride.

Authors:  Pauline Belujon; Mary H Patton; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2012-10-16       Impact factor: 5.176

8.  Neuropathological and Reelin deficiencies in the hippocampal formation of rats exposed to MAM; differences and similarities with schizophrenia.

Authors:  Julien Matricon; Alfredo Bellon; Helge Frieling; Oussama Kebir; Gwenaëlle Le Pen; Frédéric Beuvon; Catherine Daumas-Duport; Thérèse M Jay; Marie-Odile Krebs
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

9.  Hypofrontality and Posterior Hyperactivity in Early Schizophrenia: Imaging and Behavior in a Preclinical Model.

Authors:  Gen Kaneko; Basavaraju G Sanganahalli; Stephanie M Groman; Helen Wang; Daniel Coman; Jyotsna Rao; Peter Herman; Lihong Jiang; Katherine Rich; Robin A de Graaf; Jane R Taylor; Fahmeed Hyder
Journal:  Biol Psychiatry       Date:  2016-05-30       Impact factor: 13.382

10.  Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Behav Brain Res       Date:  2009-02-02       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.